The
Food and Drug Administration requested additional data from Sarepta
Therapeutics Inc. (Nasdaq: SRPT) for its New Drug Application to treat
Duchenne muscular dystrophy with eteplirsen. The stock price plummeted $7.69 to $15.87.
Sarepta must provide additional data to FDA
October 27, 2014 at 14:25 PM EDT